Satellos Announces Public Offering and Nasdaq Listing

Got story updates? Submit your updates here. ›

Satellos Bioscience Inc., a clinical-stage biotechnology company developing treatments for degenerative muscle diseases, announced the filing of a preliminary prospectus supplement for a proposed public offering of its common shares. The company also filed an application to list its common shares on the Nasdaq Global Market in the United States. Satellos intends to use the net proceeds from the offering to fund ongoing research and development activities, working capital, and general corporate purposes.

Why it matters

The proposed public offering and Nasdaq listing represent important milestones for Satellos as it seeks to advance the development of its lead drug candidate, SAT-3247, for the treatment of Duchenne muscular dystrophy and potentially other muscle diseases. Access to public capital markets and a U.S. stock exchange listing could help Satellos attract more investor attention and funding to support its clinical programs.

The details

Satellos filed the preliminary prospectus supplement in connection with the proposed public offering of its common shares (or pre-funded warrants to purchase common shares) in Canada and the United States. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares offered. The final terms of the offering will be determined at the time of pricing. The closing of the offering will be subject to customary conditions, including required approvals from the Toronto Stock Exchange and Nasdaq.

• Satellos filed the preliminary prospectus supplement on February 6, 2026.
• The company expects trading of its common shares on Nasdaq to commence following the pricing of the offering.

What’s next

The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC and on SEDAR+.